retatrutide phase 3 trials Lilly's triple agonist achieves 16.8% weight loss in trial The numbers from Lilly's Phase

ROSCA and Subscription Billing Disclosure

Scientists Are Studying GLP-1s for Broader Health Benefits in Bipolar Disorder These include metabolic liver disease, polycystic ovary syndrome (PCOS), and binge eating disorder, says Roger McIntyre, MD, a professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit of the University Health Network in Toronto

Biased agonism: one receptor, different signals Signaling does not stop at the G protein

At 9mg, the rate was 8.8%

New England Journal of Medicine 2021;384:9891002

In total, gross spending under Medicare Part D was $240 billion in 2022